The interface of malignant and immunologic clonal dynamics in high-grade serous ovarian cancer
暂无分享,去创建一个
Richard A. Moore | Yi Kan Wang | Scott D. Brown | Allen W. Zhang | A. Bashashati | A. Bouchard-Côté | Thomas Zeng | R. Holt | W. Wasserman | S. Shah | A. McPherson | D. Huntsman | Kane Tse | Andrew Roth | C. Gilks | Winnie Yang | J. McAlpine | Michael Mayo | Yinyin Yuan | B. Nelson | A. Wan | C. Nielsen | Julie Ho | Henrik Failmezger | K. Milne | Samuel Aparicio | Maia A. Smith | A. Karnezis | J. Lim | A. Heindl | Tyler Funnell | D. Cochrane | David R. Kroeger | P. Hamilton | A. Miranda | Sonya Laan | Inna Shlafman | R. Moore | Camila P. E. de Souza | D. Lai | S. Brown | Sohrab P. Shah | S. Laan | Camila P E de Souza
[1] Harini Veeraraghavan,et al. Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient , 2017, Cell.
[2] Ali Bashashati,et al. Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes , 2017, Nature Genetics.
[3] B. Monk,et al. The role of immune checkpoint inhibition in the treatment of ovarian cancer , 2016, Gynecologic Oncology Research and Practice.
[4] E. Birney,et al. Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration , 2016, Nature Communications.
[5] Yinyin Yuan,et al. Similarity and diversity of the tumor microenvironment in multiple metastases: critical implications for overall and progression-free survival of high-grade serous ovarian cancer , 2016, Oncotarget.
[6] A. Talhouk,et al. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy , 2016, Clinical Cancer Research.
[7] K. Schmetterer,et al. Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer , 2016, Oncotarget.
[8] Ali Bashashati,et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer , 2016, Nature Genetics.
[9] R. Kuick,et al. Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer , 2016, Cell.
[10] Nicolai J. Birkbak,et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.
[11] B. Nelson,et al. Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer , 2016, Clinical Cancer Research.
[12] Andrea Sottoriva,et al. Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine , 2016, Trends in cancer.
[13] A. Cesano. nCounter® PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA) , 2015, Journal of Immunotherapy for Cancer.
[14] George Coukos,et al. Targeting Programmed Cell Death 1 in Ovarian Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. George,et al. Efficient molecular subtype classification of high‐grade serous ovarian cancer , 2015, The Journal of pathology.
[16] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Sidra Nawaz,et al. Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer , 2015, Modern Pathology.
[18] B. Nelson. New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer. , 2015, Current opinion in immunology.
[19] Evis Sala,et al. Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis , 2015, PLoS medicine.
[20] N. Hacohen,et al. Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.
[21] G. Freeman,et al. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. , 2015, Cancer discovery.
[22] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[23] G. Coukos,et al. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. , 2014, Cancer discovery.
[24] R. Holt,et al. Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer , 2013, Clinical Cancer Research.
[25] Ali Bashashati,et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling , 2013, The Journal of pathology.
[26] D. Cox,et al. B cell exchange across the blood-brain barrier in multiple sclerosis. , 2012, The Journal of clinical investigation.
[27] F. Markowetz,et al. Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic Profiling , 2012, Science Translational Medicine.
[28] P. Watson,et al. CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27− Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer , 2012, Clinical Cancer Research.
[29] G. Coukos,et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. , 2012, Gynecologic oncology.
[30] H. Mackay,et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.
[31] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[32] Andrew Menzies,et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.
[33] A. Getis. The Analysis of Spatial Association by Use of Distance Statistics , 2010 .
[34] A. Tutt,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.
[35] George Coukos,et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.
[36] M. Pagel. Inferring the historical patterns of biological evolution , 1999, Nature.